

October 25, 2024

Name of listed company: Chugai Pharmaceutical Co., Ltd.  
Code number: 4519 (Prime Market of Tokyo Stock Exchange)  
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo  
President & CEO: Osamu Okuda  
Inquiries to: Kae Miyata  
Head of Corporate Communications Dept.  
Tel: +81-(0)3-3273-0554

## Notice of Revisions to Dividend Forecast for Fiscal Year Ending December 31, 2024

[Chugai Pharmaceutical Co., Ltd.](#) announced that the Company resolved at the meeting of its Board of Directors held on October 25, 2024 to revise the dividend forecast per share as described below.

### 1. Reasons for the revision

Reflecting the significant changes in the business environment, year-end dividend forecast has been revised to Undecided. The year-end dividends will be decided after the fiscal year end based on basic profit distribution principles\*. Simultaneously, the Company made a timely disclosure today through an announcement titled “Notice of Revisions to Financial Forecasts” and made upward revisions in the forecasts of revenue, core operating profit, and core earnings per share in the consolidated financial forecasts (core basis) for the fiscal year ending December 2024.

\*Regarding income distribution, taking into account the strategic funding needs and earning prospects, Chugai aims for a consolidated dividend payout ratio of 45% on average in comparison with Core EPS to provide a stable allocation of profit to all shareholders.

### 2. Contents of the revision

	Annual dividends per share		
	End of second quarter	End of FY	Total
Previous forecast	JPY 41.00	JPY 41.00	JPY 82.00
Revised forecast		Undecided	Undecided
Results for FY ending Dec. 2024	JPY 41.00		
Results for FY ending Dec. 2023	JPY 40.00	JPY 40.00	JPY 80.00

###